Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21)

Ying Wang; Weiyang Li; Suning Chen; Huiying Qiu; Aining Sun; Depei Wu

doi:10.1016/j.leukres.2010.11.003

Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21)

Leuk Res. 2011 May;35(5):604-7. doi: 10.1016/j.leukres.2010.11.003. Epub 2010 Dec 3.

Authors

Ying Wang¹, Weiyang Li, Suning Chen, Huiying Qiu, Aining Sun, Depei Wu

Affiliation

¹ Department of Hematology, First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China.

PMID: 21130493
DOI: 10.1016/j.leukres.2010.11.003

Abstract

High expression levels of granulocyte colony stimulating factor (G-CSF) receptor were found in the leukemic cells of acute myeloid leukemia (AML) patients with t(8;21). Therapeutic significance of G-CSF receptor on chemotherapy remains to be defined. We evaluate the efficacy and tolerability of CAG regimen, consisting of concurrent use of G-CSF with low-dose cytarabine and aclarubicin, in 36 refractory/relapsed AML patients with t(8;21). The overall complete remission (CR) rate was 75% and median CR duration was 12 months. No significant treatment-related adverse events were observed. These data demonstrate that CAG regimen might be an alternative option in the treatment of AML with t(8;21), especially in older patients or patients with co-morbidities.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aclarubicin / administration & dosage
Aclarubicin / adverse effects
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Chemotherapy, Adjuvant
Child
Chromosomes, Human, Pair 21* / genetics
Chromosomes, Human, Pair 8* / genetics
Cytarabine / administration & dosage
Cytarabine / adverse effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Neoplasm / drug effects
Feasibility Studies
Female
Granulocyte Colony-Stimulating Factor / administration & dosage*
Granulocyte Colony-Stimulating Factor / adverse effects
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Male
Middle Aged
Recurrence
Salvage Therapy
Translocation, Genetic* / genetics
Young Adult

Substances

Cytarabine
Granulocyte Colony-Stimulating Factor
Aclarubicin